302 related articles for article (PubMed ID: 25920929)
1. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
[TBL] [Abstract][Full Text] [Related]
2. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456
[TBL] [Abstract][Full Text] [Related]
3. Small molecules, big challenges.
Cheson BD
Oncology (Williston Park); 2015 Apr; 29(4):308-c3. PubMed ID: 25920930
[No Abstract] [Full Text] [Related]
4. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
6. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
Sujobert P; Rioufol C; Salles GA
Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
[TBL] [Abstract][Full Text] [Related]
10. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
12. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Czuczman MS; Vose JM; Witzig TE; Zinzani PL; Buckstein R; Polikoff J; Li J; Pietronigro D; Ervin-Haynes A; Reeder CB
Br J Haematol; 2011 Aug; 154(4):477-81. PubMed ID: 21707581
[TBL] [Abstract][Full Text] [Related]
13. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Pongas G; Cheson BD
Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
[TBL] [Abstract][Full Text] [Related]
14. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
[TBL] [Abstract][Full Text] [Related]
15. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
[TBL] [Abstract][Full Text] [Related]
17. Current treatment strategies in Hodgkin lymphomas.
Copeland A; Younes A
Curr Opin Oncol; 2012 Sep; 24(5):466-74. PubMed ID: 22871744
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
Rosenthal A
Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
[TBL] [Abstract][Full Text] [Related]
19. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
Choe H; Ruan J
Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
[TBL] [Abstract][Full Text] [Related]
20. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]